Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Recruiting

Phase 1

Claudin 18.2 Targeted CAR-TClaudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Sponsor:

Legend Biotech USA Inc

Code:

NCT05539430

Conditions

Gastric Cancer

Gastroesophageal-junction Cancer

Esophageal Cancer

Pancreatic Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

LB1908

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-15. This information was provided to ClinicalTrials.gov by Legend Biotech USA Inc on 2025-05-25.